Q1. Could you start by giving us a brief overview of your professional background, particularly focusing on your expertise in the industry?

I have spent 15+ years running Pharma Commercial Operations for three large Pharma organizations, managing ex-US markets and all therapeutic areas. I specialize in Commercial Execution, Go-to-market strategy, Launch Planning, Omnichannel Orchestration, Sales Operations, Incentive Compensation, Forecasting, Competitive Intelligence, Pricing & Contracts, etc.

Q2. How do factors such as unmet medical needs, treatment complexity, and payer landscape influence the AI-driven commercial opportunity sizes within specific specialty therapy areas?

Pharma specialities exhibit differing payer and prescriber characteristics. The commercial opportunity/market size is fairly well understood - with or without AI. What changes with the application of AI, though, are customer journey/orchestration strategies, faster generation of regulatory evidence such as global value dossiers, clinical trial protocol generation, etc., driving quicker and more effective go-to-market strategies.

Q3. Which specialty medicine subsegments or geographies exhibit high potential driven by AI-enabled commercial insights and tailored marketing strategies?

Specialty medicine subsegments that exhibit the highest AI enablement potential are the ones with fewer payers and practitioners - like Ophthalmology, Urology, Neonatal medicine, etc. In terms of geographies, the US takes the lead here having now regulatory channels open for AI-enabled software as a medical device and AI-enabled drug development.

Q4. What emerging AI capabilities are major Life Sciences companies prioritizing for deployment in commercial operations over the next 3-5 years?

Major Life Science companies are deploying and optimizing the following AI-based commercial capabilities -

• Campaign Orchestration & Management
• Data Management & Operations
• Market Research
• Competitive Intelligence
• Forecasting

Q5. Looking ahead, which AI and analytics-driven innovations do you predict will have the greatest disruptive impact on specialty medicine commercialization and market access?

Specialty medicine commercialization will be driven by the following AI & Analytics capabilities:

• Data Operations & Synthesis
• Social Media Listening
• Dashboarding
• Ad-Hoc and BYOD (bring your own data) analytics
• Quicker and easier system Integrations

Q6. According to you, who are the top competitors in specialty medicines across oncology, ophthalmology, and hematology, and how do their commercial strategies differ?

The top competitors are the following companies :

• Merck
• Novartis
• Roche
• Pfizer
• Amgen
• AbbVie
• Eli Lilly

Q7. If you were an investor looking at companies within the space, what critical question would you pose to their senior management?

I would pose the following questions:

• What is your pipeline trying to address in the disease profile of the current therapeutic areas that you are active in?
• How are you executing on your Go-to-market strategy in the US?
• What are your top five AI investment areas, and how are these preparing the organization to be future-fit for the oncoming AI revolution?